Raetzman was also elected to the company’s Global Executive Committee. Raetzman will report directly to Humberto C. Antunes, President and CEO of Galderma S.A. Stuart Raetzman joins Galderma after 20 years with Alcon, a division of Novartis, where he held senior leadership roles in the US and Europe.
“This leadership appointment comes at a moment of great change in the dermatology industry and for those who provide services to patients,” said Antunes. “Galderma is committed to providing innovative medical solutions to people with skin needs, while working with healthcare providers around the world. The company has a strong management team with unparalleled knowledge of the dermatology market. Stuart brings a wealth of experience to that team, as well as a unique perspective that will help us innovate even further.
“Stuart is uniquely qualified to contribute to the leadership of our growing global company and to serve the changing customer needs, while remaining true to our values,” added Antunes. “Stuart’s broad and successful experience, particularly in ophthalmology, a specialty segment that has already gone through transformations similar to the ones impacting dermatology, gives him unique insights and a deep understanding of the economic, social and technological trends shaping our world. His unique track record of leading multi-business organizations, including prescription, consumer and surgical medical solutions, is of particular interest to Galderma and dermatology at large. At heart, Stuart has both a strong commitment to people and an astute vision of the future of healthcare.”
“It is an honor and a privilege to lead Galderma in North America and to contribute to the Global Executive Committee,” Raetzman said. “Galderma has a clear mission that is focused on innovation in skin care and has a successful history of delivering against that mission. The team at Galderma puts the patient at the center of all they do and they are committed to serving the healthcare professionals who care for these patients. I look forward to working with the Galderma team and with the healthcare community to drive innovation in dermatology.”
About GALDERMA Galderma is a global company founded in 1981 committed to delivering innovative medical solutions to meet the dermatological needs of people throughout their lifetime while serving healthcare professionals around the world. The company has 31 wholly-owned affiliates with a worldwide network of distributors and 5,000 employees. Galderma’s extensive product portfolio is available in 70 countries and treats a range of dermatological conditions including: acne, rosacea, onychomycosis, psoriasis & steroid-responsive dermatoses, pigmentary disorders, skin cancer and medical solutions for skin senescence. With approximately 19% of revenues invested each year to discover and develop new products and access innovative technologies, the company is one of the world’s leading investors in dermatology R&D. Five state-of-the-art R&D centers and five manufacturing sites are dedicated to providing a wide range of innovative medical solutions which meet the highest standards of safety and efficacy. Strategic brands include Epiduo®, Oracea®, Clobex®, Differin®, Rozex®/MetroGel®, Mirvaso®, Silkis®/Vectical®, Tri-Luma®, Loceryl®, Cetaphil®, Metvix®, Azzalure®, Restylane® and Emervel®.
SOURCE Galderma S.A.
